Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Millennium Management LLC

Millennium Management LLC lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1,808.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 450,872 shares of the specialty pharmaceutical company’s stock after purchasing an additional 427,246 shares during the quarter. Millennium Management LLC owned about 0.71% of Jazz Pharmaceuticals worth $48,122,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Hsbc Holdings PLC grew its stake in Jazz Pharmaceuticals by 2,454.2% during the fourth quarter. Hsbc Holdings PLC now owns 49,117 shares of the specialty pharmaceutical company’s stock worth $5,993,000 after buying an additional 47,194 shares during the period. Allianz Asset Management GmbH lifted its holdings in shares of Jazz Pharmaceuticals by 59.0% during the 4th quarter. Allianz Asset Management GmbH now owns 24,640 shares of the specialty pharmaceutical company’s stock valued at $3,031,000 after acquiring an additional 9,146 shares in the last quarter. Bank of Nova Scotia boosted its position in Jazz Pharmaceuticals by 565.9% during the 4th quarter. Bank of Nova Scotia now owns 11,153 shares of the specialty pharmaceutical company’s stock worth $1,372,000 after purchasing an additional 9,478 shares during the period. Eagle Asset Management Inc. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $2,179,000. Finally, APG Asset Management US Inc. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $1,389,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Wells Fargo & Company reduced their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Finally, Piper Sandler lowered their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $173.07.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $111.41 on Tuesday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $137.38. The firm’s 50-day simple moving average is $111.02 and its 200-day simple moving average is $110.74. The firm has a market cap of $7.03 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. Equities analysts forecast that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.